Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07828639
Starting soon Phase 1/2

A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo

NCT07828639 · tracked via the Priya Life Science China tracker
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Phase
Phase 1/2
Started
2026-09-25
Last updated
2026-09-18

Condition(s) studied

Non-Segmental Vitiligo

Investigational drug(s) / intervention(s)

VC005 tablets →

VC005 tablets: VC005 repeat administration for up to 24 weeks

Study summary

This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo

Eligibility

Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF). * Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 30 kg. * Subjects with a clinical diagnosis of non-segmental vitiligo Exclusion Criteria: * Pregnant or breastfeeding women, or subjects planning to become pregnant or breastfeed during the study period. * Trial participants with complete depigmentation of hair within the vitiligo area. * Trial participants clinically diagnosed with segmental vitiligo, mucosal non-segmental vitiligo, or other cutaneous depigmentation disorders.

Primary outcome measure(s)

  • Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC） — Day1，Day28
  • Peak Plasma Concentration (Cmax） — Day1，Day28

Trial sites (1)

FacilityCityRegionStatus
The Peking University People's Hospital Beijing Beijing Municipality

More Jiangsu vcare pharmaceutical technology co., LTD trials in China

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. Recruiting
Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects Starting soon
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Recruiting
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) Recruiting
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo Recruiting

Other trials for the same condition

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo Recruiting
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo Recruiting
Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo Starting soon
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07828639 on ClinicalTrials.gov ↗ ← All trials in China